Compare Hinge Health Inc. Class A Common Stock (HNGE) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs DENTSPLY SIRONA Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while DENTSPLY SIRONA Inc trades at $8.47 (market cap $1.70B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 5× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| HNGE | XRAY | |
|---|---|---|
Market Cap | $8.48B | $1.70B |
Volume | 879,799 | 3,939,845 |
Sector | Health | Health |
52-Week High | $105.14 | $14.68 |
52-Week Low | $31.17 | $8.44 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $8.10B | $3.77B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
XRAY trades at $8.44, down 1.06% on the day and near its 52-week low, reflecting persistent bearish technical signals. The company reported a net loss of $598 million in 2025, with negative profit margins and declining revenue, though Q2 2026 earnings beat expectations. Debt-to-asset ratio has risen to 42.88% in 2025, indicating increased financial leverage amid ongoing restructuring efforts.
The outlook remains challenging with weak profitability and high debt, but analyst consensus suggests potential upside to a $13.00 price target. Key risks include margin pressure, competitive threats, and execution of the turnaround plan. Investment appeal hinges on successful operational improvements and sustained earnings recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
